394 related articles for article (PubMed ID: 33902595)
41. Hepatitis C elimination among people incarcerated in prisons: challenges and recommendations for action within a health systems framework.
Akiyama MJ; Kronfli N; Cabezas J; Sheehan Y; Thurairajah PH; Lines R; Lloyd AR;
Lancet Gastroenterol Hepatol; 2021 May; 6(5):391-400. PubMed ID: 33857445
[TBL] [Abstract][Full Text] [Related]
42. Competing priorities and second chances - A qualitative exploration of prisoners' journeys through the Hepatitis C continuum of care.
Crowley D; Cullen W; Lambert JS; Van Hout MC
PLoS One; 2019; 14(9):e0222186. PubMed ID: 31509571
[TBL] [Abstract][Full Text] [Related]
43. [Hepatitis C in prisons : Treatment and barriers to the elimination goals of the United Nations].
Dichtl A; Jamin D; Stöver H; Grabski M; Knorr B
Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2024 Jan; 67(1):36-44. PubMed ID: 38155308
[TBL] [Abstract][Full Text] [Related]
44. Hepatitis C education and support in Australian prisons: preliminary findings of a nationwide survey.
Dyer J; Tolliday L
Health Promot J Austr; 2009 Apr; 20(1):37-41. PubMed ID: 19402814
[TBL] [Abstract][Full Text] [Related]
45. Prevention of Hepatitis C by Screening and Treatment in U.S. Prisons.
He T; Li K; Roberts MS; Spaulding AC; Ayer T; Grefenstette JJ; Chhatwal J
Ann Intern Med; 2016 Jan; 164(2):84-92. PubMed ID: 26595252
[TBL] [Abstract][Full Text] [Related]
46. Barriers and facilitators to hepatitis C (HCV) screening and treatment-a description of prisoners' perspective.
Crowley D; Van Hout MC; Lambert JS; Kelly E; Murphy C; Cullen W
Harm Reduct J; 2018 Dec; 15(1):62. PubMed ID: 30538000
[TBL] [Abstract][Full Text] [Related]
47. Palliative and end-of-life care in prisons: a content analysis of the literature.
Maschi T; Marmo S; Han J
Int J Prison Health; 2014; 10(3):172-97. PubMed ID: 25764177
[TBL] [Abstract][Full Text] [Related]
48. The effect of direct-acting antiviral regimens and telemedicine on the treatment of inmates with hepatitis C virus infection in Israeli prisons.
Richter V; Goldstein L; Cohen DL; Bermont A; Zelnik Yovel D; Madar M; Rabinovitch R; Shirin H; Broide E
Sci Prog; 2022; 105(2):368504221105173. PubMed ID: 35722762
[TBL] [Abstract][Full Text] [Related]
49. Detection, stratification and treatment of hepatitis C-positive prisoners in the United Kingdom prison estate: Development of a pathway of care to facilitate the elimination of hepatitis C in a London prison.
Connoley D; Francis-Graham S; Storer M; Ekeke N; Smith C; Macdonald D; Rosenberg W
J Viral Hepat; 2020 Oct; 27(10):987-995. PubMed ID: 32449969
[TBL] [Abstract][Full Text] [Related]
50. Incidence and correlates of hepatitis C virus infection in a large cohort of prisoners who have injected drugs.
Snow KJ; Young JT; Preen DB; Lennox NG; Kinner SA
BMC Public Health; 2014 Aug; 14():830. PubMed ID: 25113132
[TBL] [Abstract][Full Text] [Related]
51. Elimination of hepatitis C virus in a prison: An 18-year experience.
Nogales-Garcia M; Parraza Diez N; Vargas Axpe A; Velasco Garcia R; Larrabeiti-Etxebarria A; Roy Lopez-Cano I; Atrio Alvarez I; Lopez de Arcaute Trincado A; Fernandez Lopez de Vicuña EM; Saez de Adana Arroniz E; Martínez Martínez C; Portu Zapirain J
Enferm Infecc Microbiol Clin (Engl Ed); 2024 May; 42(5):236-241. PubMed ID: 37117143
[TBL] [Abstract][Full Text] [Related]
52. "That was quick, simple, and easy": Patient perceptions of acceptability of point-of-care hepatitis C RNA testing at a reception prison.
Lafferty L; Cochrane A; Sheehan Y; Treloar C; Grebely J; Lloyd AR
Int J Drug Policy; 2022 Jan; 99():103456. PubMed ID: 34560624
[TBL] [Abstract][Full Text] [Related]
53. The role of prison-based interventions for hepatitis C virus (HCV) micro-elimination among people who inject drugs in Montréal, Canada.
Godin A; Kronfli N; Cox J; Alary M; Maheu-Giroux M
Int J Drug Policy; 2021 Feb; 88():102738. PubMed ID: 32278651
[TBL] [Abstract][Full Text] [Related]
54. Personality disorders do not affect treatment outcomes for chronic HCV infection in Spanish prisoners: the Perseo study.
Marco A; Antón JJ; Trujols J; Saíz de la Hoya P; de Juan J; Faraco I; Caylà JA;
BMC Infect Dis; 2015 Aug; 15():355. PubMed ID: 26286450
[TBL] [Abstract][Full Text] [Related]
55. Prevalence of HCV in prisons in Wales, UK and the impact of moving to opt-out HCV testing.
Perrett SE; Plimmer A; Shankar AG; Craine N
J Public Health (Oxf); 2020 May; 42(2):423-428. PubMed ID: 32090269
[TBL] [Abstract][Full Text] [Related]
56. Real-life experience of hepatitis C treatment in a Spanish prison.
Tejera-Pérez RJ; Iglesias-Gómez A; Oliva-Oliva A; Rodríguez-Alonso B; Alonso-Sardón M; Sánchez Ledesma M; Carbonell-Muñoz C; Pendones Ulerio J; Muñoz-Bellido JL; Belhassen-García M
Rev Esp Quimioter; 2022 Jun; 35(3):273-278. PubMed ID: 35441836
[TBL] [Abstract][Full Text] [Related]
57. Hepatitis C virus infection in EU/EEA and United Kingdom prisons: opportunities and challenges for action.
Nakitanda AO; Montanari L; Tavoschi L; Mozalevskis A; Duffell E
BMC Public Health; 2020 Nov; 20(1):1670. PubMed ID: 33167912
[TBL] [Abstract][Full Text] [Related]
58. Five Questions Concerning Managing Hepatitis C in the Justice System: Finding Practical Solutions for Hepatitis C Virus Elimination.
Spaulding AC; Adee MG; Lawrence RT; Chhatwal J; von Oehsen W
Infect Dis Clin North Am; 2018 Jun; 32(2):323-345. PubMed ID: 29778259
[TBL] [Abstract][Full Text] [Related]
59. Enhancing assessment and treatment of hepatitis C in the custodial setting.
Post JJ; Arain A; Lloyd AR
Clin Infect Dis; 2013 Aug; 57 Suppl 2():S70-4. PubMed ID: 23884069
[TBL] [Abstract][Full Text] [Related]
60. Hepatitis C in European prisons: a call for an evidence-informed response.
Arain A; Robaeys G; Stöver H
BMC Infect Dis; 2014; 14 Suppl 6(Suppl 6):S17. PubMed ID: 25252822
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
